Tags

Type your tag names separated by a space and hit enter

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
J Cyst Fibros. 2012 May; 11(3):163-72.JC

Abstract

BACKGROUND

There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic fibrosis (CF) respiratory pathogens such as Pseudomonas aeruginosa and MRSA.

METHODS

The antimicrobial activity of a novel 4:1 (w/w) fosfomycin:tobramycin (F:T) combination against CF respiratory pathogens under both aerobic and anaerobic conditions was determined by MIC, time-kill and biofilm studies, and compared with activity of fosfomycin and tobramycin, individually.

RESULTS

F:T and fosfomycin had excellent activity against P. aeruginosa and were more active than tobramycin against P. aeruginosa under anaerobic conditions with lower MIC(50), MIC(90) and geometric mean values. F:T (p<0.001) and fosfomycin (p<0.001) MICs for P. aeruginosa were significantly lower under anaerobic conditions with tobramycin MICs significantly higher (p<0.001). F:T and fosfomycin also had high activity against MRSA with both being more active than tobramycin. In time-kill studies, F:T was rapidly bactericidal against all 15 P. aeruginosa and 3/5 MRSA isolates tested. F:T also demonstrated bactericidal activity against P. aeruginosa grown in biofilm under both aerobic and anaerobic conditions.

CONCLUSIONS

F:T has promising in vitro antimicrobial activity against MRSA and P. aeruginosa with greater activity under anaerobic conditions similar to those found in the CF lung.

Authors+Show Affiliations

CF and Airways Microbiology Research Group, Queen's University Belfast, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22138067

Citation

McCaughey, Gerard, et al. "Antimicrobial Activity of Fosfomycin and Tobramycin in Combination Against Cystic Fibrosis Pathogens Under Aerobic and Anaerobic Conditions." Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, vol. 11, no. 3, 2012, pp. 163-72.
McCaughey G, McKevitt M, Elborn JS, et al. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros. 2012;11(3):163-72.
McCaughey, G., McKevitt, M., Elborn, J. S., & Tunney, M. M. (2012). Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 11(3), 163-72. https://doi.org/10.1016/j.jcf.2011.11.003
McCaughey G, et al. Antimicrobial Activity of Fosfomycin and Tobramycin in Combination Against Cystic Fibrosis Pathogens Under Aerobic and Anaerobic Conditions. J Cyst Fibros. 2012;11(3):163-72. PubMed PMID: 22138067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. AU - McCaughey,Gerard, AU - McKevitt,Matt, AU - Elborn,J Stuart, AU - Tunney,Michael M, Y1 - 2011/12/03/ PY - 2011/06/01/received PY - 2011/10/31/revised PY - 2011/11/10/accepted PY - 2011/12/6/entrez PY - 2011/12/6/pubmed PY - 2012/11/7/medline SP - 163 EP - 72 JF - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society JO - J Cyst Fibros VL - 11 IS - 3 N2 - BACKGROUND: There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic fibrosis (CF) respiratory pathogens such as Pseudomonas aeruginosa and MRSA. METHODS: The antimicrobial activity of a novel 4:1 (w/w) fosfomycin:tobramycin (F:T) combination against CF respiratory pathogens under both aerobic and anaerobic conditions was determined by MIC, time-kill and biofilm studies, and compared with activity of fosfomycin and tobramycin, individually. RESULTS: F:T and fosfomycin had excellent activity against P. aeruginosa and were more active than tobramycin against P. aeruginosa under anaerobic conditions with lower MIC(50), MIC(90) and geometric mean values. F:T (p<0.001) and fosfomycin (p<0.001) MICs for P. aeruginosa were significantly lower under anaerobic conditions with tobramycin MICs significantly higher (p<0.001). F:T and fosfomycin also had high activity against MRSA with both being more active than tobramycin. In time-kill studies, F:T was rapidly bactericidal against all 15 P. aeruginosa and 3/5 MRSA isolates tested. F:T also demonstrated bactericidal activity against P. aeruginosa grown in biofilm under both aerobic and anaerobic conditions. CONCLUSIONS: F:T has promising in vitro antimicrobial activity against MRSA and P. aeruginosa with greater activity under anaerobic conditions similar to those found in the CF lung. SN - 1873-5010 UR - https://www.unboundmedicine.com/medline/citation/22138067/Antimicrobial_activity_of_fosfomycin_and_tobramycin_in_combination_against_cystic_fibrosis_pathogens_under_aerobic_and_anaerobic_conditions_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1569-1993(11)00209-8 DB - PRIME DP - Unbound Medicine ER -